Status:

COMPLETED

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Melanoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this stu...

Eligibility Criteria

Inclusion

  • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
  • Key Inclusion Criteria
  • Diagnosis of advanced melanoma
  • Prior treatment in a prespecified prior/parent ipilimumab study
  • Men and women 18 years of age and older
  • First Reinduction:
  • No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation
  • Had experienced documented progressive disease after expanded clinical benefit
  • Extended Maintenance
  • Received ipilimumab at any dose in a parent study
  • Achieved expanded clinical benefit at the time of entry to current study
  • Follow-up:
  • Received ipilimumab at any dose in a closing parent study
  • Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up
  • Key Exclusion Criteria
  • Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
  • Primary ocular or mucosal melanoma

Exclusion

    Key Trial Info

    Start Date :

    May 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2014

    Estimated Enrollment :

    248 Patients enrolled

    Trial Details

    Trial ID

    NCT00162123

    Start Date

    May 1 2006

    End Date

    April 1 2014

    Last Update

    July 27 2016

    Active Locations (58)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 15 (58 locations)

    1

    University Of Arizona Cancer Center

    Tucson, Arizona, United States, 85719

    2

    Wilshire Oncology Medical Group Inc

    Laverne, California, United States, 91750

    3

    The Angeles Clinic & Research Inst.

    Los Angeles, California, United States, 90025

    4

    Usc/Norris Comprehensive Cancer Center

    Los Angeles, California, United States, 90033